SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Meeting) on June 13, 2017 at the Companys corporate headquarters
located at 11500 S. Eastern Avenue, Suite 240, Henderson, Nevada
89052. As of April 17, 2017, the record date for the Annual
Meeting, a total of 80,443,922 shares were entitled to vote, of
which a total of 70,980,202 shares were present in person or by
proxy at the Annual Meeting constituting a quorum for the conduct
of business thereat.
results at the Annual Meeting for each of the matters voted upon by
the stockholders. These matters are described in more detail in the
Company’s definitive proxy statement on Schedule 14A, which the
Company filed with the Securities and Exchange Commission on April
17, 2017 (the “Proxy Statement”).
named below to serve on the Companys Board of Directors for a
one-year term expiring at the annual meeting of stockholders in
2018 and until their respective successors are duly elected and
qualified, or until their earlier resignation or removal.
|
Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
Raymond W. Cohen
|
37,223,271
|
17,098,120
|
16,658,811
|
|
Gilles R. Gagnon
|
41,004,858
|
13,316,533
|
16,658,811
|
|
Stuart M. Krassner
|
38,013,573
|
16,307,818
|
16,658,811
|
|
Luigi Lenaz
|
26,225,190
|
28,096,201
|
16,658,811
|
|
Anthony E. Maida
|
37,003,558
|
17,317,833
|
16,658,811
|
|
Rajesh C. Shrotriya
|
40,804,085
|
13,517,306
|
16,658,811
|
|
Dolatrai Vyas
|
37,613,210
|
16,708,181
|
16,658,811
|
executive compensation detailed in the Proxy Statement.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
23,752,273
|
30,309,362
|
259,756
|
16,658,811
|
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
vote on executive compensation should be every year, by a vote as
follows.
|
Annual
|
Bi-Annual
|
Tri-Annual
|
Abstentions
|
|
44,264,130
|
188,932
|
9,724,272
|
144,057
|
stockholder advisory vote to approve executive compensation every
year, until the next stockholder advisory vote on the frequency of
the stockholder advisory vote to approve executive compensation. A
stockholder advisory vote on the frequency of stockholder advisory
votes to approve executive compensation is required to be held at
least once every six years.
Touche LLP as the independent registered public accounting firm for
the year ending December 31, 2017.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
69,866,460
|
752,040
|
361,702
|
|
majority voting, as detailed in the Proxy Statement.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
46,720,648
|
7,203,144
|
397,599
|
16,658,811
|
Committee, acknowledges the votes for the foregoing proposals at
the annual meeting, including the advisory vote on executive
compensation, and looks forward to continuing a constructive
dialogue with the stockholders in the coming months.
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.